Responsible prescribing for cosmetic procedures

Abstract

This article describes the context and challenges that relate to prescribing in the non-surgical aesthetic sector and sets out the Joint Council for Cosmetic Practitioners position regarding responsible prescribing of prescription-only medicines used in aesthetic practice. The guidance lines up with that set down by the majority of the professional healthcare regulators and by the Royal Pharmaceutical Society. With regard to delegated prescribing, prescribers are reminded that patients remain under the oversight of the prescriber, requiring them to be familiar with the patient through an initial face-to-face consultation and diagnostic assessment of the patient's suitability for treatment. This applies to the routine/planned/repeat administration of medicines that are used specifically for cosmetic purposes, such as botulinum toxins, injected local anaesthetic or topical adrenaline, and the emergency use of medicines, such as hyaluronidase. Prescribers are also reminded of their obligation to address the existence of competing interests and to place the needs of the patient first, being transparent about their actions. Readers are also directed to relevant legislation and professional guidance that is applicable to the sector.